NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 206 filers reported holding NEVRO CORP in Q1 2021. The put-call ratio across all filers is 0.60 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $195,045 | -23.9% | 10,148 | +0.7% | 0.00% | -100.0% |
| Q2 2023 | $256,183 | -38.8% | 10,078 | -13.0% | 0.00% | 0.0% |
| Q1 2023 | $418,545 | -8.7% | 11,578 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $458,489 | -30.2% | 11,578 | -17.9% | 0.00% | -50.0% |
| Q3 2022 | $657,000 | +6.3% | 14,098 | 0.0% | 0.00% | +100.0% |
| Q2 2022 | $618,000 | -39.1% | 14,098 | +0.6% | 0.00% | -50.0% |
| Q1 2022 | $1,014,000 | -10.7% | 14,018 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $1,136,000 | -30.3% | 14,018 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $1,631,000 | -27.8% | 14,018 | +2.9% | 0.00% | -25.0% |
| Q2 2021 | $2,258,000 | +19.5% | 13,618 | +0.6% | 0.00% | 0.0% |
| Q1 2021 | $1,889,000 | -22.2% | 13,538 | -3.5% | 0.00% | -20.0% |
| Q4 2020 | $2,428,000 | +19.1% | 14,028 | -4.1% | 0.01% | 0.0% |
| Q3 2020 | $2,038,000 | +22.5% | 14,628 | +5.0% | 0.01% | +25.0% |
| Q2 2020 | $1,664,000 | +14.6% | 13,928 | -4.1% | 0.00% | 0.0% |
| Q1 2020 | $1,452,000 | -14.1% | 14,518 | +0.9% | 0.00% | 0.0% |
| Q4 2019 | $1,691,000 | +19.7% | 14,388 | -12.5% | 0.00% | 0.0% |
| Q3 2019 | $1,413,000 | +23.5% | 16,438 | -6.8% | 0.00% | +33.3% |
| Q2 2019 | $1,144,000 | +16.7% | 17,639 | +12.5% | 0.00% | 0.0% |
| Q1 2019 | $980,000 | +60.7% | 15,679 | 0.0% | 0.00% | +50.0% |
| Q4 2018 | $610,000 | -29.4% | 15,679 | +3.5% | 0.00% | 0.0% |
| Q3 2018 | $864,000 | -28.6% | 15,154 | 0.0% | 0.00% | -33.3% |
| Q2 2018 | $1,210,000 | -4.7% | 15,154 | +3.4% | 0.00% | 0.0% |
| Q1 2018 | $1,270,000 | +20.3% | 14,654 | -4.2% | 0.00% | 0.0% |
| Q4 2017 | $1,056,000 | -22.0% | 15,293 | +2.7% | 0.00% | -25.0% |
| Q3 2017 | $1,353,000 | +22.1% | 14,893 | 0.0% | 0.00% | +33.3% |
| Q2 2017 | $1,108,000 | +9.1% | 14,893 | +37.4% | 0.00% | 0.0% |
| Q1 2017 | $1,016,000 | +28.9% | 10,842 | 0.0% | 0.00% | +50.0% |
| Q4 2016 | $788,000 | -29.5% | 10,842 | +1.3% | 0.00% | -33.3% |
| Q3 2016 | $1,117,000 | +56.2% | 10,702 | +10.4% | 0.00% | +50.0% |
| Q2 2016 | $715,000 | +43.3% | 9,692 | +9.3% | 0.00% | 0.0% |
| Q1 2016 | $499,000 | -9.6% | 8,870 | +8.4% | 0.00% | 0.0% |
| Q4 2015 | $552,000 | – | 8,180 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Iron Triangle Partners LP | 562,833 | $40,710,000 | 4.84% |
| Altium Capital Management LP | 77,000 | $5,569,000 | 1.86% |
| PFM Health Sciences, LP | 649,513 | $46,979,000 | 1.76% |
| Rock Springs Capital Management LP | 721,500 | $52,186,000 | 1.31% |
| Integral Health Asset Management, LLC | 50,000 | $3,617,000 | 0.94% |
| Redmile Group, LLC | 411,017 | $29,729,000 | 0.93% |
| K2 PRINCIPAL FUND, L.P. | 114,800 | $8,303,000 | 0.72% |
| Connacht Asset Management LP | 18,762 | $1,357,000 | 0.70% |
| Perceptive Advisors | 477,037 | $34,504,000 | 0.69% |
| ArrowMark Colorado Holdings LLC | 855,439 | $61,874,000 | 0.54% |